A global equity firm well-versed in pharmaceutical investing is betting the ongoing frenzy in weight-loss drug stock has further to run.
Novo Nordisk and Eli Lilly are among top holdings in the A$1.3 billion Capital Group New Perspective Fund, which is beating 94 per cent of peers this year, according to data compiled by Bloomberg. The long-standing fund, which first invested in the two companies long before recent fervour for obesity treatments, claims ...
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: